Stayble Therapeutics AB (STABL) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.219x

Based on the latest financial reports, Stayble Therapeutics AB (STABL) has a cash flow conversion efficiency ratio of -0.219x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.85 Million ≈ $-198.87K USD) by net assets (Skr8.46 Million ≈ $910.00K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Stayble Therapeutics AB - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Stayble Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Stayble Therapeutics AB debt and liabilities for a breakdown of total debt and financial obligations.

Stayble Therapeutics AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Stayble Therapeutics AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Virpax Pharmaceuticals Inc NASDAQ:VRPX	3.142x
PCI Biotech Holding ASA OL:PCIB	-0.501x
Groupimo SA PA:ALIMO	0.026x
Sejahtera Bintang Abadi Textile Tbk JK:SBAT	-0.023x
Baltic Bridge S.A. WAR:WIS	N/A
M Winkworth PLC LSE:WINK	0.157x
VATIC VENTURES CORP. F:V8V	N/A
Alchimie Sa PA:ALCHI	0.739x

Annual Cash Flow Conversion Efficiency for Stayble Therapeutics AB (2016–2024)

The table below shows the annual cash flow conversion efficiency of Stayble Therapeutics AB from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Stayble Therapeutics AB.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr6.87 Million ≈ $739.64K	Skr-14.67 Million ≈ $-1.58 Million	-2.134x	-49.66%
2023-12-31	Skr16.51 Million ≈ $1.78 Million	Skr-23.54 Million ≈ $-2.53 Million	-1.426x	+12.45%
2022-12-31	Skr15.28 Million ≈ $1.64 Million	Skr-24.89 Million ≈ $-2.68 Million	-1.628x	-572.99%
2021-12-31	Skr39.81 Million ≈ $4.28 Million	Skr-9.63 Million ≈ $-1.04 Million	-0.242x	+84.31%
2020-12-31	Skr15.55 Million ≈ $1.67 Million	Skr-23.98 Million ≈ $-2.58 Million	-1.542x	-57.46%
2019-12-31	Skr-295.44K ≈ $-31.79K	Skr289.39K ≈ $31.14K	-0.980x	-28.49%
2018-12-31	Skr7.11 Million ≈ $765.43K	Skr-5.42 Million ≈ $-583.53K	-0.762x	-140.22%
2017-12-31	Skr8.25 Million ≈ $887.43K	Skr-2.62 Million ≈ $-281.63K	-0.317x	-152.05%
2016-12-31	Skr11.06 Million ≈ $1.19 Million	Skr-1.39 Million ≈ $-149.87K	-0.126x	--

About Stayble Therapeutics AB

ST:STABL Sweden Biotechnology

Market Cap

$271.50K

Skr2.52 Million SEK

Market Cap Rank

#30734 Global

#731 in Sweden

Share Price

Skr0.04

Change (1 day)

-13.66%

52-Week Range

Skr0.03 - Skr0.52

All Time High

Skr16.95